Nasdaq: GENB · Listed Feb 27, 2026
Generate Biomedicines IPO
IPO price
$16.00
Generate Biomedicines (GENB) priced its IPO at $16.00 a share and has traded on Nasdaq since Feb 27, 2026.
GENB today$10.60-33.75%since IPO15-min delayed · as of 4:59:14 AM EST on Nov 19, 2026
See the GENB quoteFirst trading day · Feb 27, 2026
- IPO price
- $16.00
- inside the range of $15 to $17
- First trade
- $15.00
- -6.25% from the IPO price
- First-day last trade
- $12.94
- -19.13% from the IPO price, regular session
- Raise
- $400M
- before the underwriters' option
These numbers are from the first trading day, Feb 27, 2026.
How GENB did against the market
GENB against the market, from its first trade at 12:50 ET to the last trade of the session.
- GENB from its first trade
- -13.73%
- Against the market (QQQ)
- -14.0 pts
GENB fell 13.7% from its first trade to the last trade of the session. That is 14.0 points worse than the market.
Same-day moves do not show that GENB caused them. The market is QQQ, the Nasdaq-100 ETF.
The debut race
GENB against other big listings, as the percent change from each stock's own IPO price.
The first 30 trading days. Each point is the last regular-session trade of a day.
The first trading day.
The first trading day.
The IPO scoreboard
GENB against 6 other big listings: the return from each IPO's own price at the first trade, the close of day 1, day 5, and day 30.
| IPO | Raised | First trade | Day 1 close | Day 1 close, as a bar | Day 5 | Day 30 |
|---|---|---|---|---|---|---|
| Generate Biomedicines '26 | $400M | -6.25% | -19.13% | -22.12% | -28.56% | |
| Figma '25 | $1.22B | +157.58% | +252.42% | +173.64% | +69.64% | |
| Circle '25 | $1.05B | +122.58% | +168.45% | +278.18% | +622.98% | |
| Reddit '24 | $748M | +38.24% | +47.97% | +69.90% | +40.32% | |
| Arm '23 | $5.23B | +10.00% | +23.76% | +3.63% | -3.06% | |
| Klarna '25 | $1.37B | +30.00% | +16.14% | +13.73% | -7.33% | |
| CoreWeave '25 | $1.5B | -2.50% | +0.02% | +34.32% | +28.42% |
Day 1 is the last regular-session trade of the first day. Day 5 and day 30 are the last trade of the fifth and thirtieth trading day, counting the listing day as day 1. A cell fills in when that day has traded.
The offering
The Generate Biomedicines IPO offers 25M shares to raise $400M, before any underwriters' option.
- Expected price range
- $15 to $17
- IPO price
- $16.00
- Shares offered
- 25M
- Money raised
- $400M
- Listing date
- Feb 27, 2026
- Exchange
- Nasdaq
- Security
- Ordinary Shares
Money raised, against the largest IPOs
- Alibaba '14$21.77B
- Facebook '12$18.41B
- Rivian '21$11.93B
- Uber '19$8.1B
- Arm '23$5.23B
- Generate Biomedicines$400M
Where GENB ranks
Generate Biomedicines's market cap against the largest US-listed companies.
Market cap, against the largest US-listed companies
- AAPL$5.12T
- MSFT$3.77T
- NVDA$3.65T
- GOOGL$3.47T
- AMZN$2.9T
- TSM$1.88T
- AVGO$1.69T
- META$1.58T
- TSLA$1.52T
- BRK.B$1.22T
- GENB$1.34B
GENB news
The latest news and headlines about Generate Biomedicines (GENB).
- 2027 Could Finally Be the Year Cancer Is on the Ropes!positiveGlobeNewswire Inc.· Oct 29, 2026
- Pharmaceutical Market Research: Global Industry to Reach USD 3.22 Trillion by 2035 as Biologics, AI-Driven Drug Discovery, and Manufacturing Investments Reshape CompetitionpositiveGlobeNewswire Inc.· Oct 16, 2026
- Cathie Wood Likes That New Stock Smell: 3 IPO Stocks She Bought on MondaypositiveThe Motley Fool· Jul 7, 2026
- Nvidia Owns This Under-the-Radar $20 Stock Poised to Disrupt a $1.8 Trillion MarketpositiveThe Motley Fool· Jun 27, 2026
- A Deep Dive Into Nvidia’s Latest Portfolio MovespositiveInvesting.com· May 20, 2026
- Severe Asthma Clinical Trial Pipeline Appears Robust With 30+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight | DelveInsightpositiveGlobeNewswire Inc.· Apr 7, 2026
Filings and the company
What Generate Biomedicines has disclosed to the SEC, and the basic facts about the listing.
8-K filings
Material events that Generate Biomedicines discloses to the SEC on Form 8-K.
- Quarterly earningsNov 12, 2026
On November 12, 2026, Generate Biomedicines, Inc. (the "Company") issued a press release reporting its financial results for the quarter ended September 30, 2026.
- Clinical trial resultsAug 26, 2026
Draft copies of three posters submitted by Generate Biomedicines, Inc. include results of ongoing clinical trials sponsored by the Company, entitled: 'GB-0895, a next-generation anti-TSLP mAb, demonstrates durable pharmacologic activity supporting a single subcutaneous injection every 6 months for asthma patients'; 'SOLAIRIA-1 & SOLAIRIA-2: Two Phase 3 randomized, double-blind, placebo-controlled studies of GB-0895, a long-acting anti-TSLP antibody, in severe uncontrolled asthma'; and 'GB-0895, a High-Affinity Anti-TSLP Antibody, Demonstrates Potent and Sustained Pharmacological Activity in Adults with COPD.'
- Charter amendmentMar 2, 2026
The Company filed its amended and restated certificate of incorporation (the 'Amended and Restated Certificate') with the Secretary of State of the State of Delaware on March 2, 2026... to, among other things: (i) authorize 500,000,000 shares of common stock; (ii) eliminate all references to the previously-existing series of preferred stock; (iii) authorize 10,000,000 shares of undesignated preferred stock that may be issued from time to time by the Board in one or more series; and (iv) eliminate the ability of the Company's stockholders to take action by written consent in lieu of a meeting and call special meetings of stockholders.
About Generate Biomedicines
Generate Biomedicines Inc is a clinical-stage generative biology company pioneering the AI revolution in biotechnology and drug design and development. The company's single operating segment is engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics. Its product candidates include: GB-0895, GB-4362, and GB-5267. Through the company's Generate Platform, it can generate medicines on demand across multiple therapeutic modalities with unprecedented speed representing a fundamental shift in drug discovery.
- Ticker
- GENB
- Exchange
- Nasdaq
- Market
- stocks
- Type
- CS
- Currency
- USD
- Industry
- PHARMACEUTICAL PREPARATIONS
- Listed
- Feb 27, 2026
- Security
- Ordinary Shares
Frequently asked questions
What was the Generate Biomedicines IPO price?
$16.00 a share.
When did Generate Biomedicines go public?
Generate Biomedicines listed on Nasdaq on Feb 27, 2026 under the ticker GENB.
How much did the Generate Biomedicines IPO raise?
$400M, before any underwriters' option.
How did Generate Biomedicines open on its first day?
GENB first traded at $15.00, -6.25% from the IPO price of $16.00.
How did GENB close on its first day?
Its last regular-session trade was $12.94, -19.13% from the IPO price of $16.00.
What was the GENB first-day trading range?
$11.44 to $15.32 in the regular session.
How many GENB shares traded on the first day?
5.82M shares in the regular session.
How many shares did Generate Biomedicines sell in its IPO?
25M shares.
How did GENB do against the market on its first day?
GENB fell 13.7% from its first trade to the last trade of the session. That is 14.0 points worse than the market (QQQ, the Nasdaq-100 ETF).
What exchange is GENB listed on?
Generate Biomedicines lists on Nasdaq under the ticker GENB.
Build with Massive
Get the GENB data behind this page
| What the page shows | Endpoint |
|---|---|
| Offering terms and dates | /vX/reference/ipos |
| Price | /v3/snapshot |
| Chart, VWAP, and the market comparison | /v2/aggs/ticker/GENB/range/5/minute |
| Market cap | /v3/reference/tickers/GENB |
| News | /v2/reference/news |
| Filings | /vX/disclosures |
Nothing on this page is investment advice. All data and content is provided for informational purposes under our Terms of Service.